Efficacy of transcranial direct current stimulation in reducing impulsivity in borderline personality disorder (TIMBER): study protocol of a randomized controlled clinical trial

Trials. 2019 Jun 10;20(1):347. doi: 10.1186/s13063-019-3427-z.

Abstract

Background: Impulsivity is a core feature of borderline personality disorder (BPD) and is closely related to suicide risk and destructive and aggressive behaviors. Although transcranial direct current stimulation (tDCS) has shown its promising effects as an intervention to modulate impulsivity, no study has explored its potential regarding BPD.

Methods/design: This is a multicenter, crossover, double-blind study comparing active versus sham tDCS (2 mA, 30 min), applied over the dorsolateral prefrontal cortex for five consecutive days in 50 BPD patients. Participants will be assessed for impulsivity, depressive symptoms, and suicide risk. The main efficacy criteria on reduction of impulsivity will be the amplitude variation of one specific evoked potential detected by electroencephalography (EEG) during the balloon analogue risk task. Baseline measures will be compared to scores obtained immediately after sessions, then 12 and 30 days later.

Discussion: This study investigates the safety and effects of tDCS, which may have a significant impact on impulsivity in patients with BPD and may be useful to reduce risky behaviors.

Trial registration: ClinicalTrials.gov, NCT03498937 . Registered on 17 April 2018.

Keywords: Borderline personality disorder; Dorsolateral prefrontal cortex; Impulsivity; Risk-taking; Transcranial direct current stimulation.

Publication types

  • Clinical Trial Protocol

MeSH terms

  • Borderline Personality Disorder / psychology
  • Borderline Personality Disorder / therapy*
  • Cross-Over Studies
  • Double-Blind Method
  • Humans
  • Impulsive Behavior*
  • Multicenter Studies as Topic
  • Outcome Assessment, Health Care
  • Randomized Controlled Trials as Topic*
  • Transcranial Direct Current Stimulation / methods*

Associated data

  • ClinicalTrials.gov/NCT03498937